Zydus posts consolidated revenues of Rs. 3655 crores in Q3

The company filed 12 additional ANDAs with the USFDA during the quarter and received 9 new product approvals (including 5 tentative approvals) from the USFDA.

New Delhi: For the third quarter ended December 31, 2021, Zydus reported consolidated revenues of Rs.3655 crores. Earnings before Interest, Depreciation and Tax (EBIDTA) stood at Rs. 753 crores. Net Profit for the quarter stood at Rs. 500 crores.
India formulations business posted revenues of Rs. 1079 crores during the quarter. The branded formulations business posted a robust double-digit growth of 17% on a y-o-y basis. This is after adjusting for sales of COVID related products, generics portfolio and divested products. The company’s patented product ‘Lipaglyn’ entered the top 100 brands of the Indian pharmaceutical market and was ranked at 92. This is a jump of 183 ranks i.e. from 275 to 92 during the current quarter. On the super specialty front, the group retained the leadership position in the Nephrology market and in the oncology segment, the group is the fastest growing company in India. The group gained market share in the core therapies of anti-diabetic, cardiovascular, gynaecology and anti-infective therapeutic areas during the quarter on a y-o-y basis.
US formulations business registered revenues of Rs. 1504 crores during the quarter. The company filed 12 additional ANDAs with the USFDA during the quarter and received 9 new product approvals (including 5 tentative approvals) from the USFDA. The company launched 3 new products in the US market including Nelarabine injection which was granted 180 days exclusivity and was a day 1 launch. It is a chemotherapy drug used to treat certain types of leukemia and lymphoma.
During the quarter, the company announced positive clinical data for CUTX-101, Copper Histidinate, presented at 2021 American Academy of Pediatrics National Conference & Exhibition. Cyprium Therapeutics Inc., a partner company of Fortress Biotech Inc., with support from its licensing partner Sentynl Therapeutics, a wholly owned subsidiary of CHL is developing CUTX-101 for the treatment of Menkes disease. An initial module of a New Drug Application (NDA) of CUTX 101 was also filed with the USFDA during the quarter.
Making headway in research, the company also announced that the ‘first patient’ has been randomised in EVIDENCES-X TM Phase II(b) clinical trial of Saroglitazar Mg in Non-Alcoholic Steatohepatitis (NASH) and Fibrosis. The company also received permission from USFDA to initiate the Phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in Primary Biliary Cholangitis. The company also submitted the New Drug Application (NDA) to the DCGI for Desidustat, for the treatment of anaemia in patients with Chronic Kidney Disease (CKD) who are on Dialysis and Not on Dialysis.
The company also received permission to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin Associated Periodic Syndrome (CAPS) in Australia. Catering to the unmet critical needs, the company received Orphan Drug Designation from US FDA for ZY-19489, a novel compound to treat malaria which is currently been developed in association with Medicines for Malaria Venture (MMV).
The group has also started supplies of its COVID-19 vaccine ZyCoV-D, to the Government of India against their order from its newly commissioned state-of-the-art, Zydus Vaccine Technology Excellence Centre at the Zydus Biotech Park in Changodar, Ahmedabad. The group is also planning to make the vaccine available in the private market. ZyCoV-D is a three dose vaccine administered intradermally using the painless PharmaJet® needle free system, Tropis®, on day 0, day 28 and day 56.